Molecular Diagnostic Solutions for Urologic Cancer

2017 Company Presentation
Dr. Jan Groen, President & CEO
Mr. Jean-Marc Roelandt, EVP & CFO
Forward Looking Statement

This presentation contains forward-looking statements & estimates made by the management of the Company with respect to the anticipated future performance of MDxHealth & the market in which it operates. Such statements & estimates are based on various assumptions & assessments of known & unknown risks, uncertainties & other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict & may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of MDxHealth, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements & estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements & estimates. MDxHealth disclaims any obligation to update any such forward-looking statement or estimates to reflect any change in the Company’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement or estimate is based, except to the extent required by Belgian law.

Analyst Coverage

Any opinions, estimates or forecasts made by analysts are theirs alone and do not represent opinions, forecasts or predictions of MDxHealth or its management. Requests for copies of analyst reports should be directed at the respective analyst & institution.
MDxHealth

Company Highlights

Molecular diagnostic company
- Market leader in (uro) oncology MDx
- Proprietary MDx products

Improving diagnosis
- ConfirmMDx for Prostate Cancer
- SelectMDx for Prostate cancer

Clear value proposition
- Reimbursement in place
- 2016 E sales $~29M
Business Model & Urological MDx Cancer Market

MDxHealth

CLIA Business
LDT tests

$3 billion

IVD Business
Dx Kits

$1 billion
## Intellectual Property

### Strong Protection

<table>
<thead>
<tr>
<th>Patents</th>
<th>ROW</th>
<th>US</th>
</tr>
</thead>
<tbody>
<tr>
<td>Issued Patents</td>
<td>23</td>
<td>25</td>
</tr>
<tr>
<td>Patents Pending</td>
<td>15</td>
<td>20</td>
</tr>
<tr>
<td>Family</td>
<td>38</td>
<td></td>
</tr>
</tbody>
</table>
North America & Europe
Annual Numbers

709,134
New cases of prostate cancer

242,273
New cases of bladder cancer

1. GLOBOCAN 2012 (IARC) Population forecasts were extracted from the United Nations, World Population prospects, the 2012 revision. Numbers are computed using age-specific rates and corresponding populations for 10 age-groups.
# Products and Pipeline

## MDxHealth

<table>
<thead>
<tr>
<th>R&amp;D</th>
<th>Validation</th>
<th>Clinical Utility</th>
<th>Launch</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MDxHealth</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ConfirmMDx</strong>&lt;br&gt;for Prostate Cancer</td>
<td>US</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SelectMDx</strong>&lt;br&gt;for Prostate Cancer</td>
<td>US &amp; EU</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>AssureMDx</strong>&lt;br&gt;for Bladder Cancer</td>
<td>US &amp; EU</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>InformMDx</strong>&lt;br&gt;for Prostate Cancer</td>
<td>US &amp; EU</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RecurMDx</strong>&lt;br&gt;for Prostate Cancer</td>
<td>US &amp; EU</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Partnered

<table>
<thead>
<tr>
<th>R&amp;D</th>
<th>Validation</th>
<th>Clinical Utility</th>
<th>Launch</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Partnered</strong>&lt;br&gt;colouguard&lt;br&gt;Rx only</td>
<td>US</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MGMT</strong>&lt;br&gt;**</td>
<td>US</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Clinical Algorithm for Risk Profiling of Cancer

Nomograms combining clinical variables with molecular signatures

Clinical symptoms | Solid/Liquid biopsy | Biomarkers | Classifier

Likely Hood of Cancer

Benign

©2016 All rights reserved
Prostate Cancer Diagnosis

Standard of Care

Biopsy

Prostate

Histopathology
Prostate Cancer in the United States

Where MDxHealth Prostate Biomarkers are Indicated

Who to biopsy
(Elevated PSA)

Who to re-biopsy
(Negative biopsy result)

Who to treat
(Positive biopsy result)

Who to treat
(Post prostatectomy)

4.7M Abnormal PSA Results
1.3M Prostate Biopsies Performed
180k Cancer cases
30k Post Prostatectomy

Select MDx Health
for Prostate Cancer

Confirm MDx Health
for Prostate Cancer

Inform MDx Health
for Prostate Cancer

Recur MDx Health
for Prostate Cancer

©2016 All rights reserved
Complications Associated with Biopsies

1.1 Million negative biopsies

25% False negative result

18% of men suffer complications and about 3% are hospitalized for infection within 30 days of biopsy.

Gershman et al.; Eur Uro 2016
Loeb et al.; Eur Uro 2013
Valuable Tissue Biopsy Test for Physicians and Payors

MDxHealth lead product

The Product
- Tissue biopsy DNA test
- NPV 96%

The Urologist
- Provides actionable information
- In the NCCN guidelines

The Payors
- 57% lives covered
- Reduces healthcare spending

Confirm for Prostate Cancer
Pathology

Initial biopsy
Negative

DNA Test

Part of routine check up

Result

Likely hood risk score

Follow-up

Discuss with patient
ConfirmMDx Met all Clinical and Reimbursement Objectives

- Proprietary product validated in > 5,000 patients
- Published clinical utility and health economic studies
- Test covered by Medicare since Nov 2014
- ConfirmMDx in the NCCN guidelines
- Obtained CPT code by the AMA in 2016
SelectMDx for Prostate Cancer

Unmet Clinical Need

4.7 Million men with elevated PSA

Only 25% at risk for High Grade Prostate Cancer
Valuable Liquid Biopsy Test for Patients and Physicians
Available as LDT and IVD product

The Product
• Liquid Biopsy test
• NPV 98%

The Urologist
• Part of routine examination
• Identifies patient for MRI or biopsy

The Patient
• Non-invasive sample collection
• Easy to explain
SelectMDx for Prostate Cancer

Non-invasive, Liquid Biopsy to Identify Patients for Prostate Biopsy

Urologist

Elevated PSA
DRE

Test

Runs on any
PCR instrument

Result

Likely hood risk
score

Follow-up

Yes/No
MRi or Biopsy

routine PSA
SelectMDx on Track to Met Commercial Objectives

- Proprietary product validated in > 1,000 patients
- Health economic study submitted for publication
- Comparative study SelectMDx versus MRi completed
- Test covered by 9 payor contracts
- SelectMDx in clinical guidelines
Bladder Cancer The Most Expensive Cancer to Treat

Only cancer with decreasing 5 year survival rate

1:26 | Men lifetime risk for BCA
1:84 | Women lifetime risk for BCA
>550K | Population prevalence
$4.4B | Spent on BCA treatment

7M | Hematuria cases per annum
1M | referrals to see urologists
700K | cystoscopy procedures
72k | Cancer cases

Need for Molecular Tools to Manage Bladder Cancer

Standard of Care

Patient
Blood in Urine

Urologist
Urine sample or bladder wash

Confirmation & Location
Cytology and Cystoscopy
Market for AssureMDx in the US

Unmet Diagnostic Need

1.0 Million Hematuria Patients

700K Cystoscopy Procedures
AssureMDx Improved Identification of Patients at Risk for Bladder cancer

The Product and performance

- Test combining methylation and mutation biomarkers with clinical risk factors
- 93% sensitivity and 85% specificity
- Published multi-center validation study in Journal of Urology

The Receiver Operating Characteristic (ROC) curve shows an Area Under the Curve (AUC) of 0.96 (95% CI 0.92-0.99). The NPV is 99%.
AssureMDx for Bladder Cancer

Non-invasive, Liquid Biopsy to Identify Patients with Bladder Cancer

**Patient**
- Blood in urine

**Test**
- Runs on any open PCR/Sequence instrument

**Result**
- Likely hood risk score

**Follow-up**
- Yes/No CT scan or Cystoscopy
Commercialization
CLIA & IVD

- Laboratory developed test
- Large national sales force
- Reimbursement Medicare & Commercial

US and EU Commercialization

**CLIA Service Testing**

- $3 billion

**IVD and Service Testing**

- $1 billion
- CE marked in-vitro diagnostic kits
- Direct sales
- Distributors

Select MDx
for Prostate Cancer

Assure MDx
for Bladder Cancer

Confirm MDx
Growing Number of Ordering Physicians
Cumulative Ordering Urologists Since Launch

11,000
Urologist in the US

8,500
Office based urologists
Reimbursement & Finance
Increasing Insurance Coverage

ConfirmMDx U.S.

US Male Population Age 50 – 74

43,6m

57% of at-risk population covered

32% Medicare

66% Commercial
Continued Revenue Growth

Actual and Projected

<table>
<thead>
<tr>
<th>Year</th>
<th>Annual Revenue</th>
<th>Q3 Revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>$5.2M</td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>$7.6M</td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>$11.7M</td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>$17.6M</td>
<td></td>
</tr>
<tr>
<td>2016 P</td>
<td>~$29.0M</td>
<td>$4.1M</td>
</tr>
<tr>
<td>2016 Q3</td>
<td>$9.1M</td>
<td></td>
</tr>
</tbody>
</table>

Non-audited 2016 numbers

Cash balance in November: $32m
**Trading Info**

- **Stock Exchange**
  - EURONEXT.BR (MDXH)
  - OTC (MXDHF)

- **Total shares outstanding**
  - 49,796,595

- **52- Week range**
  - $3.18 - $5.67

- **Market Cap**
  - $265 Million

- **Analyst coverage**
  - US: - Taglich Brothers
    - van Leeuwenhoek
  - EU: - KBC
    - Degroof Petercam
    - Goetzpartners

---

**Shareholders**

- **Free Float** 73.9%
- **BioVest** 13.3%
- **Valiance** 12.8%
MDxHealth News Flow

H1 2017

- Publication of SelectMDx technical validation study
- Release outcome data SelectMDx versus MRI
- Publication SelectMDx health economic study
- Launch AssureMDx
- Expansion contracts US payors